The United States and European countries are interested in the Russian vaccine against coronavirus: the Russian Direct Investment Fund (RDIF) receives offers from them for the joint production of the domestic drug Sputnik V.
This was announced by the head of the RDIF Kirill Dmitriev in an interview with the Brazilian media, reports TASS.
“We are now being approached by people in Europe and the United States with a proposal to create partnerships for vaccine production. They finally understood how our vaccine is different, ”said Dmitriev. He specified that private companies and investment funds are showing interest in the Russian drug. He did not specify which ones.
“I can’t say more yet, but announcements can be expected in the next two weeks,” said the head of the RDIF. In his opinion, a “campaign to slander the image of the Russian drug” has been launched in the West. He also added that no one talks about the dangers of other vaccines.
Earlier, scientists from China confirmed the effectiveness of the Russian drug Triazavirin against COVID-19.
On August 11, President Vladimir Putin announced the registration of the world’s first vaccine against coronavirus Sputnik V, developed by the Gamaleya Center. The production of the drug was launched on August 15, and on September 8, the Ministry of Health announced that the first batch of the Sputnik V vaccine had been released into civil circulation. The first to receive the vaccination will be doctors and citizens at risk.